Kinase Inhibitor [EPC]

361453 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS PALBOCICLIB AXITINIB LAROTRECTINIB ABEMACICLIB ACALABRUTINIB AFATINIB AVAPRITINIB BRIGATINIB CAPMATINIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 41574
1 FATIGUE 32065
2 DIARRHOEA 29475
3 NAUSEA 21095
4 OFF LABEL USE 20170
5 RASH 14199
6 MALIGNANT NEOPLASM PROGRESSION 13403
7 ASTHENIA 13038
8 DECREASED APPETITE 12867
9 DYSPNOEA 12631
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EGFR GENE MUTATION 229 0.9160
1 CYTOGENETIC ANALYSIS ABNORMAL 373 0.5306
2 NEOPLASM PROGRESSION 10897 0.4754
3 ACQUIRED GENE MUTATION 385 0.4451
4 CHRONIC MYELOID LEUKAEMIA RECURRENT 148 0.3936
5 TRANSPLANT DYSFUNCTION 493 0.3843
6 CARBOHYDRATE ANTIGEN 15-3 INCREASED 150 0.3632
7 NON-SMALL CELL LUNG CANCER 834 0.3387
8 HAEMATOCRIT ABNORMAL 300 0.3341
9 MEDICAL PROCEDURE 192 0.3163
See all enriched reactions for Kinase Inhibitor [EPC]